Haematologica Reports 2006; 2(issue 3): 45-47[prev][index][next]

Non steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-angiogenic drugs
Rüegg C
Centre Pluridisciplinaire d’Oncologie (CePO), University of Lausanne Medical School, CH-1011 Lausanne, Switzerland, and National Center for Competence in Research (NCCR) Molecular Oncology, Swiss Institute for Experimental Cancer Research (ISREC), 155, Chemin des Boveresses, CH-1066 Epalinges, Switzerland

Non-steroidal anti-inflammatory drugs (NSAIDs) and specific inhibitors of cyclooxygenase (COX)-2, collectively referred to as COX-2 inhibitors, are therapeutics widely used for the treatment of pain, inflammation and fever. Experimental and clinical evidence indicate that COX-2 is a potential therapeutic target in cancer, and that NSAIDs and COX-2 inhibitors (COXIBs) also have anti-cancer activity.^1,2 COX-2 is expressed by cancer cells and cells of the tumor stroma during tumor progression and in response to chemotherapy or radiotherapy.
[>Read full article in PDF]